ChartRow logo
Data provided bySource: Twelve Data
ROIV
$38.71+0.26%
as of close, Nov 17, 2026
☾ AH $38.71 +0.26%
Share this page

ROIV — Roivant Sciences Ltd. price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in ROIV be worth today? →
ROIV returns: By year · By month · By week · Trailing

Price data

Price
$38.71
YTD price return
+78.39%
YTD total return
+78.39%
Market cap
28B
Enterprise value
24.5B
Shares outstanding
724.6M
52W low
$19.96
52W high
$42.50
From 52W high
-8.92%
From 52W low
+93.94%
52W range
83%$19.96–$42.50
Beta
1.12

Volume

Rel volume
1.10×
30D volume
7.7M
30D $ vol
288.4M

Insider trading

Insider net 1W
none
Insider net 1M
−$41.7M
Insider net 3M
−$63.9M
Insider net 1Y
−$526.6M

Form 4 transactions by trade date, as filed; latest on file 2026-11-11.

Fundamentals

Sales (ttm)
41.1M
Sales/share
$0.06
EPS (ttm)
-$0.48
FCF (ttm)
-33.3M
FCF/share
-$0.05
Book value/share
$5.55
Net margin
-838.21%
ROE
-8.57%
ROA
-6.92%
Current ratio
15.56

Growth (CAGR, ttm) · 10Y

Sales
+102.18%-18.08%-6.38%n/a
Shares
+4.18%-3.40%+1.14%n/a

Per-share growth (CAGR, ttm) · 10Y

Sales/share
+94.07%-16.47%-7.08%n/a
Book value/share
-11.55%+67.52%+13.27%n/a
Price
+88.36%+62.79%+36.60%n/a
Total return
+88.36%+62.79%+36.60%n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
-80.3×
Fwd P/E
-24.5×
P/S (ttm)
682.7×
P/B (mrq)
7.0×
EV/Sales (ttm)
597.1×
FCF yield (ttm)
-0.12%
Buyback yield (realized, 1y)
-4.18%
Shareholder yield (realized, 1y)
-4.18%
Buyback yield (cash, ttm)
1.80%
Shareholder yield (cash, ttm)
1.80%

Vs own 10Y history

P/S
79th
P/B
90th

Bar = where today’s multiple sits in ROIV’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
+0.26%
5D
-6.02%
1M
+15.45%
3M
+6.82%
YTD
+78.39%
1Y
+88.28%
5Y
+375.55%
1D
+0.26%
5D
-6.02%
1M
+15.45%
3M
+6.82%
YTD
+78.39%
1Y
+88.28%
5Y
+375.55%

Fundamentals#

Revenue

5Y CAGR −19.1%5Y CAGR −19.1%YoY +2135.6%
$41.1M TTM$35.1M Q2 '26
FY20FY21FY22FY23FY24FY25TTM
Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Operating income

5Y n/m5Y n/mYoY n/m
−$558M TTM−$268M Q2 '26
FY20FY21FY22FY23FY24FY25TTM
Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

EPS (diluted)

5Y n/m5Y n/mYoY n/m
−$0.48 TTM−$0.27 Q2 '26
FY20FY21FY22FY23FY24FY25TTM
Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Free cash flow

5Y n/m5Y n/mYoY n/m
−$33.3M TTM$594.2M Q2 '26
FY20FY21FY22FY23FY24FY25TTM

TTM: operating cash flow −$36.4M, capex −$3M

Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Q2 2026: operating cash flow $594.4M, capex −$208K

Shares (diluted)

5Y +10.1%5Y +10.1%YoY +6.1%
714.4M TTM722.8M Q2 '26
FY20FY21FY22FY23FY24FY25TTM
Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Net income

5Y n/m5Y n/mYoY n/m
−$344.4M TTM−$191.6M Q2 '26
FY20FY21FY22FY23FY24FY25TTM
Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Full ROIV financials →

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing medicines and technologies through a portfolio of specialized subsidiary companies. Roivant Sciences Ltd. operates across immunology, dermatology, and other high-unmet-need therapeutic areas, with current work spanning commercial products and clinical-stage candidates. Its business model emphasizes creating focused operating companies to advance individual drug programs, support partnering activities, and incubate complementary health technology initiatives. The company’s current product and pipeline portfolio includes therapies for autoimmune and inflammatory diseases, as well as treatments being studied in areas such as dermatologic conditions, uveitis, pulmonary hypertension, and rare diseases. Roivant Sciences Ltd. plays a distinctive role in the healthcare market by combining drug development expertise with an asset-centric structure designed to move promising medicines toward commercialization.

London, United Kingdom·721 employees·Biotechnology·roivant.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding ROIV#

23 of the 193 ETFs ChartRow carries live hold ROIV. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
IBBiShares Biotechnology ETF1.4%
XBISPDR S&P Biotech ETF1.2%
VBKVanguard Small-Cap Growth ETF0.5%
IJHiShares Core S&P Mid-Cap ETF0.4%
MDYSPDR S&P MidCap 400 ETF Trust0.4%
VHTVanguard Health Care ETF0.2%
VBVanguard Small-Cap ETF0.2%
VXFVanguard Extended Market ETF0.2%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%